Alpha Tau Medical (NASDAQ:DRTS) & Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Contrast

Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility and Risk

Vivos Therapeutics has a beta of 7.47, meaning that its share price is 647% more volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares Vivos Therapeutics and Alpha Tau Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$14.58 million	1.50	-$13.58 million	($5.68)	-0.65
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.45)	-6.00

Vivos Therapeutics has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Vivos Therapeutics and Alpha Tau Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	0	0	2	0	3.00
Alpha Tau Medical	0	0	2	0	3.00

Vivos Therapeutics currently has a consensus target price of $6.30, suggesting a potential upside of 69.81%. Alpha Tau Medical has a consensus target price of $8.00, suggesting a potential upside of 196.30%. Given Alpha Tau Medical’s higher probable upside, analysts plainly believe Alpha Tau Medical is more favorable than Vivos Therapeutics.

Profitability

This table compares Vivos Therapeutics and Alpha Tau Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-86.19%	-335.04%	-93.58%
Alpha Tau Medical	N/A	-38.62%	-29.89%

Institutional & Insider Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alpha Tau Medical beats Vivos Therapeutics on 6 of the 11 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.